Structural and Clinical Predictors of Cognitive Impairment After Surgical Treatment for Ruptured Cerebral Aneurysms
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Campinas, Brazil
- Trial code
- NCT07723131
- Record updated
- 23 July 2026
- Original description
This study investigates the clinical and structural predictors of long-term cognitive impairment in patients who underwent microsurgical clipping for aneurysmal subarachnoid hemorrhage. Using a retrospective cohort with prospective neuropsychological and MRI assessments, it aims to identify factors associated with late cognitive deficits and improve prognostic stratification, rehabilitation planning, and long-term patient care.Read full original descriptionShow less
Structural and Clinical Predictors of Late Cognitive Impairment After Microsurgical Clipping of Ruptured Cerebral Aneurysms: A Retrospective Cohort With Prospective Assessment
This study investigates the clinical and structural predictors of long-term cognitive impairment in patients who underwent microsurgical clipping for aneurysmal subarachnoid hemorrhage. Using a retrospective cohort with prospective neuropsychological and MRI assessments, it aims to identify factors associated with late cognitive deficits and improve prognostic stratification, rehabilitation planning, and long-term patient care.
Inclusion: Age ≥18 years at the time of aSAH; Treatment by microsurgical clipping of a ruptured cerebral aneurysm; Survival until study recruitment; Ability to understand and sign informed consent.
Exclusion: Previous diagnosis of dementia; Non-aneurysmal subarachnoid hemorrhage; Severe neurological or psychiatric disorders unrelated to aSAH with significant cognitive impact; Exclusively endovascular treatment; Absolute contraindication to MRI; Severe aphasia preventing adequate neuropsychological evaluation; Incomplete clinical data; Inability to attend in-person assessment.